drugset / Trial / NCT00423397
Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer
Phase 1/2
Unknown
16 enrolled
University of California, San Diego
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PEG-interferon alfa-2a may interfere with the growth of tumor cells and slow the growth of skin cancer. Giving gefitinib together with PEG-interferon alfa-2a may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of PEG-interferon alfa-2a when given together with gefitinib and to see how well they work in treating patients with unresectable or metastatic skin cancer.
Timeline
- Start
- 2006-09
- Primary completion
- 2008-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | — | Oral |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | — | Subcutaneous |